PUNE, India, October 17, 2017 /PRNewswire/ --
The global epigenetics market size will reach $1,605.7 million by 2022 from $854.0 million in 2017 at a CAGR of 13.5% during (2017-2022) propelled by the decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer according to RnRMarketResearch.
Browse 191 Market Data Tables and 37 Figures spread through 230 Pages and in-depth TOC on "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022" http://www.rnrmarketresearch.com/epigenetics-technology-market-epigenomics-dna-methylation-histone-modifications-rna-interference-cancer-therapeutics-personalized-medicine-2012-2017-market-report.html .
The prominent players in the epigenetics market include Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).
North America accounted for the largest share of the global epigenetics market in 2016, while Asia Pacific is projected to register the highest growth rate during the forecast period. The global epigenetics market is broadly segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa. Factors such as increasing R&D spending, favorable government initiatives, and rising focus of key market players on enhancing their presence in this region are supporting the growth of the epigenetics market in the Asia Pacific.
Make an Inquiry on Epigenetics Market Global Forecast to 2022 research report at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=68045 .
The oncology segment dominated the Global Epigenetics Market, by Application, in 2016. On the basis of application, the epigenetics market is segmented into oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and other applications (includes neurology, gynecology, and infectious diseases). In 2016, the oncology segment accounted for the major share of the global epigenetics market. The large share of this segment is attributed to the rising prevalence of cancer and the increasing number of research-related activities.
On the basis of end users, the epigenetics market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations (CROs). The pharmaceutical and biotechnology companies segment is expected to register the highest CAGR during the forecast period, owing to increasing research in the areas of genomics with a strong focus on personalized medicine.
Inquire for Discount on "Epigenetics Market Global Forecast to 2022" research report at http://www.rnrmarketresearch.com/contacts/discount?rname=68045 .
The breakup of primary participants has been mentioned below:
- By Company Type: Tier 1 - 35%, Tier 2 - 40% and Tier 3 - 25%
- By Designation: C Level - 33%, Director Level - 41%, Others - 26%
- By Region: North America - 35%, Europe - 30%, Asia Pacific - 21%, and RoW - 14%
The report aims at estimating the market size and future growth potential of the epigenetics market for different segments such as product, application, technology, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and market strategies.
Another research titled Digital PCR and Real-time PCR (qPCR) Market Forecast to 2022 says, the global dPCR and qPCR market is estimated to grow at a CAGR of 8.9% from 2017 to 2022, to reach $5.31 billion by 2022. The dPCR technology segment to grow at faster pace than qPCR technology segment during the forecast period. The dPCR instruments segment is expected to grow at the highest CAGR during 2017-2022. Asia-Pacific to witness the highest growth during the forecast period (2017-2022). Companies such as Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (U.S.), Agilent Technologies Inc. (U.S.), bio Mérieux S.A. (France), Fluidigm Corporation (U.S.), Danaher Corporation (U.S.), Abbott Laboratories (U.S.) have been profiled in this 215 pages research report available at http://www.rnrmarketresearch.com/digital-pcr-and-real-time-pcr-qpcr-market-by-technology-qpcr-dpcr-product-instrument-reagent-application-oncology-blood-testing-pathogen-detection-research-forensic-end-user-hospital-diagnostic-ce-st-to-2022-market-report.html .
Explore more reports on Biotechnology Market at http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
2nd Floor, Metropole Building,
Next to Inox Theatre,
Bund Garden Road, Pune - 411001.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed